Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First‐in‐Patient Study Designs in Psoriasis
Authors:
Open Access
- 24 July 2013
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 2 (7) , 1-9
Abstract
Clinical trial simulation (CTS) and model‐based meta‐analysis (MBMA) can increase our understanding of small, first‐in‐patient (FIP) trial design performance to inform Phase 2 decision making. In this work, we compared dose‐ranging designs vs. designs testing only placebo and the maximum dose for early decision making in psoriasis. Based on MBMA of monoclonal antibodies in the psoriasis space, a threshold of greater than a 50 percentage point improvement over placebo effect at the highest feasible drug dose was required for the advancement in psoriasis. Studies testing only placebo and the maximum dose made the correct advancement decision marginally more often than dose‐ranging designs in the majority of the cases. However, dose‐ranging studies in FIP trials offer important design advantages in the form of dose–response (D–R) information to inform Phase 2 dose selection. CTS can increase the efficiency and quality of drug development decision making by studying the limitations and benefits of study designs prospectively. CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e58; doi:10.1038/psp.2013.32; published online 24 July 2013Keywords
This publication has 27 references indexed in Scilit:
- A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisCurrent Medical Research and Opinion, 2007
- Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's DiseasePharmaceutical Research, 2006
- Model-based development of gemcabene, a new lipid-altering agentThe AAPS Journal, 2005
- Therapeutic Benefit of Eletriptan Compared to Sumatriptan for the Acute Relief of Migraine Pain — Results of a Model-Based Meta-Analysis that Accounts for EncapsulationCephalalgia, 2005
- Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe PsoriasisPharmaceutical Research, 2005
- How Modeling and Simulation Have Enhanced Decision Making in New Drug DevelopmentJournal of Pharmacokinetics and Pharmacodynamics, 2005
- The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.Pharmaceutical Research, 2003
- Role of modelling and simulation in Phase I drug developmentEuropean Journal of Pharmaceutical Sciences, 2001
- Clinical Trial Simulation in Drug DevelopmentPharmaceutical Research, 2000
- Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their qualityBritish Journal of Dermatology, 1999